Long-Term Prognosis of Pure and Impure Tachycardiomyopathy
ESC Heart Failure · 01.12.2025 · 12 (6) · 4288-4298
DOI: 10.1002/ehf2.15444 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 09.10.2025. Verfasst von Giulia Stronati und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Marche University Hospital, Ancona, Italy. Hauptthemen laut MEDLINE: Cardiomyopathies, Stroke Volume, Heart Failure, Tachycardia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marche Polytechnic University.
Abstract (Originalsprache)
Background and aims Tachycardia-induced cardiomyopathy (TCM) is a reversible form of heart failure (HF) driven by arrhythmias, often atrial fibrillation (AF). While reversible, TCM's long-term prognosis remains unclear, especially in comparison to HF with reduced ejection fraction (HFrEF). This study examines the prognosis of pure and impure TCM against other causes of HFrEF.
Methods
Prospective, monocentric, observational study of 456 patients hospitalized with de novo, acute decompensated HFrEF, classified into pure TCM, impure TCM, ischaemic HF and non-ischaemic HF. The primary endpoint was all-cause mortality, and the secondary endpoint was the incidence of unplanned cardiovascular hospitalisations. Sensitivity analyses were performed using propensity score matching between the four groups.
Results
During a median follow-up of 3 years (interquartile range 1.5–5.1 years), pure TCM had the highest survival rate, and ischaemic HF had the lowest (pure TCM 78.2%; impure TCM 64.8%; non-ischaemic HF 73.4%; ischaemic HF 58.5%; log-rank P < 0.0001). Pure and impure TCM presented the lowest free-from-readmission estimates over follow-up (pure TCM 43.2%; impure TCM 60.0%; non-ischaemic HF 83.2%; ischaemic HF 69.9%; log-rank P < 0.0001). An initial rhythm control strategy was associated with better overall survival in TCM (79% vs. 63%; log-rank P < 0.0001) but similar rates of unplanned hospitalization.
Conclusions
Pure TCM shows a favourable survival prognosis but high readmission rates, emphasizing the need for early rhythm control and sustained monitoring for arrhythmia recurrence. An initial rhythm control strategy seems associated with an increased survival, highlighting the importance of early recognition of arrhythmias as a culprit of HF worsening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Marche University Hospital, Ancona, Italy.
- Cardiology and Intensive Care Unit, IRCCS INRCA, Ancona, Italy.
- Cardiology and Arrhythmology Clinic, Marche University Hospital, Ancona, Italy.
- Department of Odontostomatologic and Specialized Clinical Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy.
ORCID-Profile: Federico Guerra
Förderung
- Marche Polytechnic University
Zitieren
APA
Stronati, G., Alfieri, M., Tombolesi, N., Barbarossa, A., Principi, S., Gullì, F., Massari, A., Bastianoni, G., Roccetti, F., Casella, M., Dello Russo, A., & Guerra, F. (2025). Long-Term Prognosis of Pure and Impure Tachycardiomyopathy. ESC Heart Failure, 12(6), 4288-4298. https://doi.org/10.1002/ehf2.15444
Vancouver
Stronati G, Alfieri M, Tombolesi N, Barbarossa A, Principi S, Gullì F, et al. Long-Term Prognosis of Pure and Impure Tachycardiomyopathy. ESC Heart Failure. 2025;12(6):4288-4298. doi:10.1002/ehf2.15444
BibTeX
@article{Stronati2025,
author = {Stronati, Giulia and Alfieri, Michele and Tombolesi, Niki and Barbarossa, Alessandro and Principi, Samuele and Gullì, Federico and Massari, Arianna and Bastianoni, Gianmarco and Roccetti, Francesca and Casella, Michela and Dello Russo, Antonio and Guerra, Federico},
title = {Long-Term Prognosis of Pure and Impure Tachycardiomyopathy},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {6},
pages = {4288--4298},
doi = {10.1002/ehf2.15444}
}
EUVIMED